Skip to Content

Liraglutide

In the US, Liraglutide (liraglutide systemic) is a member of the drug class incretin mimetics and is used to treat Diabetes - Type 2, Obesity and Weight Loss.

US matches:

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

A10BJ02

CAS registry number (Chemical Abstracts Service)

0204656-20-2

Chemical Formula

C172-H265-N43-O51

Molecular Weight

3751

Therapeutic Categories

Antidiabetic agent: Incretin-mimetic, glucagon-like peptide-1 (GLP-1) agonist

Antiobesity agent: glucagon-like peptide-1 (GLP-1) agonist

Chemical Names

Arg³⁴Lys²⁶-(N-epsilon(gamma-Glu(N-α-hexadecanoyl)))-GLP-1[7-37] (USAN)

Lys²⁶(Nepsilon(gamma-glutamyl-(Nα-hexadecanoyl))), Arg³⁴-GLP-1(7-37)

N²⁶-(hexadecanoyl-gamma-glutamyle)-[34-arginine]GLP-1-(7-37)-peptide (WHO)

N²⁶-(N-Hexadecanoyl-L-gamma-glutamyl)-[34-L-arginine]glucagon-like peptide 1-(7-37)-peptide (USAN)

Foreign Names

  • Liraglutidum (Latin)
  • Liraglutid (German)
  • Liraglutide (French)
  • Liraglutida (Spanish)

Generic Names

Brand Names

  • Saxenda
    Novo Nordisk, United States
  • Victoza
    Laboratorio Novo Nordisk, Chile; Novo Nordisk, Argentina; Novo Nordisk, Austria; Novo Nordisk, Australia; Novo Nordisk, Bosnia & Herzegowina; Novo Nordisk, Bangladesh; Novo Nordisk, Belgium; Novo Nordisk, Canada; Novo Nordisk, Switzerland; Novo Nordisk, China; Novo Nordisk, Colombia; Novo Nordisk, Czech Republic; Novo Nordisk, Germany; Novo Nordisk, Denmark; Novo Nordisk, Spain; Novo Nordisk, Finland; Novo Nordisk, France; Novo Nordisk, United Kingdom; Novo Nordisk, Georgia; Novo Nordisk, Greece; Novo Nordisk, Hong Kong; Novo Nordisk, Croatia (Hrvatska); Novo Nordisk, Hungary; Novo Nordisk, Ireland; Novo Nordisk, Israel; Novo Nordisk, Iceland; Novo Nordisk, Italy; Novo Nordisk, Japan; Novo Nordisk, Lebanon; Novo Nordisk, Lithuania; Novo Nordisk, Latvia; Novo Nordisk, Mexico; Novo Nordisk, Malaysia; Novo Nordisk, Netherlands; Novo Nordisk, Norway; Novo Nordisk, Oman; Novo Nordisk, Philippines; Novo Nordisk, Poland; Novo Nordisk, Portugal; Novo Nordisk, Serbia; Novo Nordisk, Russian Federation; Novo Nordisk, Sweden; Novo Nordisk, Slovakia; Novo Nordisk, Thailand; Novo Nordisk, Tunisia; Novo Nordisk, Turkey; Novo Nordisk, United States; Novo Nordisk, South Africa
  • Xultophy (Liraglutide and Insulin Degludec)
    Novo Nordisk, Switzerland; Novo Nordisk, Germany; Novo Nordisk, United Kingdom; Novo Nordisk, Poland

International Drug Name Search

Glossary

TermDefinition
BANBritish Approved Name
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Hide